rs10486552
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBS1BS2
The NM_152740.4(HIBADH):c.252+771A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00855 in 152,332 control chromosomes in the GnomAD database, including 12 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.0086 ( 12 hom., cov: 33)
Consequence
HIBADH
NM_152740.4 intron
NM_152740.4 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.607
Publications
1 publications found
Genes affected
HIBADH (HGNC:4907): (3-hydroxyisobutyrate dehydrogenase) This gene encodes a mitochondrial 3-hydroxyisobutyrate dehydrogenase enzyme. The encoded protein plays a critical role in the catabolism of L-valine by catalyzing the oxidation of 3-hydroxyisobutyrate to methylmalonate semialdehyde. [provided by RefSeq, Nov 2011]
HIBADH Gene-Disease associations (from GenCC):
- 3-hydroxyisobutyric aciduriaInheritance: AR Classification: LIMITED Submitted by: ClinGen
- inborn organic aciduriaInheritance: AR Classification: LIMITED Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.93).
BS1
Variant frequency is greater than expected in population sas. GnomAd4 allele frequency = 0.00855 (1303/152332) while in subpopulation SAS AF = 0.0301 (145/4824). AF 95% confidence interval is 0.0261. There are 12 homozygotes in GnomAd4. There are 627 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 12 AR gene
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| HIBADH | NM_152740.4 | c.252+771A>G | intron_variant | Intron 2 of 7 | ENST00000265395.7 | NP_689953.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00855 AC: 1302AN: 152214Hom.: 12 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
1302
AN:
152214
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.00855 AC: 1303AN: 152332Hom.: 12 Cov.: 33 AF XY: 0.00842 AC XY: 627AN XY: 74480 show subpopulations
GnomAD4 genome
AF:
AC:
1303
AN:
152332
Hom.:
Cov.:
33
AF XY:
AC XY:
627
AN XY:
74480
show subpopulations
African (AFR)
AF:
AC:
108
AN:
41570
American (AMR)
AF:
AC:
215
AN:
15308
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
3470
East Asian (EAS)
AF:
AC:
22
AN:
5184
South Asian (SAS)
AF:
AC:
145
AN:
4824
European-Finnish (FIN)
AF:
AC:
27
AN:
10624
Middle Eastern (MID)
AF:
AC:
2
AN:
294
European-Non Finnish (NFE)
AF:
AC:
770
AN:
68036
Other (OTH)
AF:
AC:
13
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
64
127
191
254
318
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
66
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.